ADXN
- Addex Therapeutics Ltd
()
Overview
Company Summary
Addex Therapeutics Ltd (ADXN) is a biopharmaceutical company that specializes in the development of drugs targeting orphan diseases, which are rare and often overlooked medical conditions. The company focuses on discovering and designing highly selective, orally available small molecule drugs known as allosteric modulators.
Addex Therapeutics has expertise in allosteric modulation, a unique therapeutic approach that allows for fine-tuning of specific biological pathways involved in disease. By targeting allosteric sites on key receptors or enzymes, their drugs can modulate the activity of these proteins, leading to therapeutic effects.
The company's drug discovery and development pipeline primarily focuses on the central nervous system (CNS) and immuno-inflammatory diseases. In CNS disorders, Addex Therapeutics is targeting conditions such as Parkinson's disease, epilepsy, and addiction. In immuno-inflammatory diseases, their research is aimed at addressing conditions like asthma and multiple sclerosis.
Addex Therapeutics utilizes various techniques for drug discovery, including high-throughput screening, in vitro testing, and in vivo preclinical models. They also collaborate with academic institutions, pharmaceutical companies, and contract research organizations to advance their drug candidates.
Overall, Addex Therapeutics aims to bring innovative treatments to patients suffering from rare and debilitating diseases, improving their quality of life and potentially filling significant unmet medical needs.